Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam

Anh Duc Dang(National Institute Of Hygiene And Epidemiology), Rami Scharf(Program for Appropriate Technology in Health), Peter Palese(Icahn School of Medicine at Mount Sinai), Adolfo García‐Sastre(Office of Infectious Diseases), Duoc Van Nguyen(Institute of Vaccine and Medical Biologicals), Laina D. Mercer(Program for Appropriate Technology in Health), Juan Manuel Carreño(Icahn School of Medicine at Mount Sinai), Anh Thi Van Pham(Hanoi Medical University), Vũ Đình Thiểm(National Institute Of Hygiene And Epidemiology), Stefan Slamanig(Icahn School of Medicine at Mount Sinai), Manjari Lal(Program for Appropriate Technology in Health), Saranath Lawpoolsri(Mahidol University), Ha Hai Vu(National Institute Of Hygiene And Epidemiology), José Luis Martínez(Icahn School of Medicine at Mount Sinai), Ariel Raskin(Icahn School of Medicine at Mount Sinai), Johnstone Tcheou(Icahn School of Medicine at Mount Sinai), Florian Krammer(Semmelweis University), Be Van Le(Institute of Vaccine and Medical Biologicals), Thai Huu Duong(Institute of Vaccine and Medical Biologicals), Rama Raghunandan(Program for Appropriate Technology in Health), Pailinrut Chinwangso(Mahidol University), Bruce L. Innis(Universidad de Los Andes, Chile), Jessica A. White(Program for Appropriate Technology in Health), Huong Minh Vu(National Institute Of Hygiene And Epidemiology), Irene González‐Domínguez(Icahn School of Medicine at Mount Sinai), Thang Cong Tran(Hanoi University of Pharmacy), Huong Mai Nguyen(Sungkyunkwan University), Ching‐Lin Hsieh(Asia University), Richard Hjorth(Program for Appropriate Technology in Health), Van Thanh Ta(Hanoi Medical University), Weina Sun(Icahn School of Medicine at Mount Sinai), Mai Thị Ngọc Đặng(Hanoi Medical University), Jason S. McLellan(The University of Texas at Austin)
medRxiv
February 5, 2022
Cited by 3


Related Papers